Rheumatoid arthritis
Conditions
Brief summary
The primary endpoint of this study is the percentage of rheumatoid arthritis patients in remission (DAS28-CRP < 2,6) at three months.
Detailed description
Disease activity remission at 6, 9 and 12 months, Disease activity scores and components at 3, 6, 9, and 12 months, Changes in biomarkers: CRP and ESR, Time to diseases activity remission and remission duration, Patient-reported outcome measures, Adherence to treatment, Patient satisfaction, Adverse events: incidence and severity (side effects), Direct and indirect costs, The cumulative dosage of corticosteroids over the study period, The cumulative usage of bDMARDs over the study period
Interventions
Sponsors
Medisch Spectrum Twente
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study is the percentage of rheumatoid arthritis patients in remission (DAS28-CRP < 2,6) at three months. | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease activity remission at 6, 9 and 12 months, Disease activity scores and components at 3, 6, 9, and 12 months, Changes in biomarkers: CRP and ESR, Time to diseases activity remission and remission duration, Patient-reported outcome measures, Adherence to treatment, Patient satisfaction, Adverse events: incidence and severity (side effects), Direct and indirect costs, The cumulative dosage of corticosteroids over the study period, The cumulative usage of bDMARDs over the study period | — |
Countries
Netherlands
Outcome results
None listed